Molecular and functional imaging of breast cancer

Cancer Control

Volumn 17, Issue 3, 2010, Pages 143-155

  Tafreshi, Narges K ^a   Kumar, Virendra ^a   Morse, David L ^a   Gatenby, Robert A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; BEVACIZUMAB; BRCA1 PROTEIN; DOCETAXEL; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PACLITAXEL; THYMIDINE; TRASTUZUMAB; URIDINE;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER SCREENING; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG RESPONSE; HUMAN; INTERMETHOD COMPARISON; MAMMOGRAPHY; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; SCINTIMAMMOGRAPHY; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE;

EID: 77954963568     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481001700302     Document Type: Article

References (139)

1. Heywang SH, Hilbertz T, Beck R, et al. Gd-DTPA enhanced MR imaging of the breast in patients with postoperative scarring and silicon implants. J ComputAssist Tomogr. 1990;14(3):348-356.
2. Vandermeer FQ, Bluemke DA. Breast MRI: state of the art. Cancer Invest. 2007;25(6):384-392.
3. Kuhl C. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology. 2007;244(2):356-378.
4. Li J, Yu Y, Zhang Y, et al. A clinically feasible method to estimate pharmacokinetic parameters in breast cancer. Med Phys. 2009;36(8):3786-3794.
5. Bassett LW, Dhaliwal SG, Eradat J, et al. National trends and practices in breast MRI. AJR Am J Roentgenol. 2008;191(2):332-339.
6. Bedrosian I, Mick R, Orel SG, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer. 2003;98(3):468-473.
7. Kuhl CK. Current status of breast MR imaging. Part 2. Clinical applications. Radiology. 2007;244(3):672-691.
8. Orel S. Who should have breast magnetic resonance imaging evaluation? J Clin Oncol. 2008;26(5):703-711.
9. Patani N, Mokbel K. The utility of MRI for the screening and staging of breast cancer. Int J Clin Pract. 2008;62(3):450-453.
10. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23(33):8469-8476.
11. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365(9473):1769-1778.
12. Trecate G, Vergnaghi D, Manoukian S, et al. MRI in the early detection of breast cancer in women with high genetic risk. Tumori. 2006;92(6):517-523.
13. Griebsch I, Brown J, Boggis C, et al. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mam-mography of women at a high familial risk of breast cancer. Br J Cancer. 2006; 95(7):801-810.
14. Mann RM, Kuhl CK, Kinkel K, et al. Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol. 2008;18(7):1307-1318.
15. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75-89.
16. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233(3):830-849.
17. Mumtaz H, Hall-Craggs MA, Davidson T, et al. Staging of symptomatic primary breast cancer with MR imaging. AJR Am J Roentgenol. 1997;169(2):417-424.
18. Van Goethem M, Tjalma W, Schelfout K, et al. Magnetic resonance imaging in breast cancer. Eur J Surg Oncol. 2006;32(9):901-910.
19. Esserman L, Hylton N, Yassa L, et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved pre-operative staging. J Clin Oncol. 1999;17(1):110-119.
20. Dummin LJ, Cox M, Plant L. Prediction of breast tumor size by mam-mography and sonography - a breast screen experience. Breast. 2007; 16(1):38-46.
21. Boetes C, Mus RD, Holland R, et al. Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology. 1995;197(3):743-747.
22. Onesti JK, Mangus BE, Helmer SD, et al. Breast cancer tumor size: correlation between magnetic resonance imaging and pathology measurements. Am J Surg. 2008;196(6):844-848; discussion 849-850.
23. Mann RM, Veltman J, Barentsz JO, et al. The value of MRI compared to mammography in the assessment of tumour extent in invasive lobular carcinoma of the breast. Eur J Surg Oncol. 2008;34(2):135-142.
24. Uematsu T, Yuen S, Kasami M, et al. Comparison of magnetic resonance imaging, multidetector row computed tomography, ultrasonography, and mammography for tumor extension of breast cancer. Breast Cancer Res Treat. 2008;112(3):461-474.
25. Hata T, Takahashi H, Watanabe K, et al. Magnetic resonance imaging for preoperative evaluation of breast cancer: a comparative study with mammography and ultrasonography. J Am Coll Surg. 2004;198(2):190-197.
26. Kuhl C, Kuhn W, Braun M, et al. Pre-operative staging of breast cancer with breast MRI: one step forward, two steps back? Breast. 2007;16 (suppl 2):S34-S44.
27. Morrow M. Should routine breast cancer staging include MRI? Nat Clin Pract Oncol. 2009;6(2):72-73.
28. Abraham DC, Jones RC, Jones SE, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer. 1996;78(1):91-100.
29. Balu-Maestro C, Chapellier C, Bleuse A, et al. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat. 2002;72(2):145-152.
30. Cheung YC, Chen SC, Su MY, et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat. 2003;78(1):51-58.
31. Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004;14(8):1371-1379.
32. Partridge SC, Gibbs JE, Lu Y, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005;184(6):1774-1781.
33. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol. 2005;184(3):868-877.
34. Gillies R, Guinebretiere JM, Toussaint C, et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology. 1994;191(3):633-638.
35. Pickles MD, Lowry M, Manton DJ, et al. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005;91(1):1-10.
36. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2008;14(20):6580-6589.
37. Tsuboi N, Ogawa Y, Inomata T, et al. Changes in the findings of dynamic MRI by preoperative CAF chemotherapy for patients with breast cancer of stage II and III: pathologic correlation. Oncol Rep. 1999;6(4):727-732.
38. Johansen R, Jensen LR, Rydland J, et al. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using dCe-MRI. J Magn Reson Imaging. 2009; 29(6):1300-1307.
39. Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 2008;112(1):17-26.
40. Rieber A, Zeitler H, Rosenthal H, et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol. 1997;70(833):452-458.
41. Mumtaz H, Davidson T, Spittle M, et al. Breast surgery after neoad-juvant treatment. Is it necessary? Eur J Surg Oncol. 1996;22(4):335-341.
42. Loo CE, Teertstra HJ, Rodenhuis S, et al. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol. 2008;191(5):1331-1338.
43. Soderstrom CE, Harms SE, Farrell RS Jr, et al. Detection with MR imaging of residual tumor in the breast soon after surgery. AJR Am J Roentgenol. 1997;168(2):485-488.
44. Orel SG, Reynolds C, Schnall MD, et al. Breast carcinoma: MR imaging before re-excisional biopsy. Radiology. 1997;205(2):429-436.
45. Frei KA, Kinkel K, Bonel HM, et al. MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging. AJR Am J Roentgenol. 2000;175(6):1577-1584.
46. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35(8):1308-1312.
47. Mavi A, Urhan M, Yu JQ, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47(9):1440-1446.
48. Santiago JF, Gonen M, Yeung H, et al. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging. 2006;50(1):61-67.
49. Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev. 2008;27(4):545-554.
50. Phelps ME, Mazziotta JC, Schelbert HR, eds. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. New York, NY: Raven Press; 1986.
51. Rose C, Dose J, Avril N. Positron emission tomography for the diagnosis of breast cancer. Nucl Med Commun. 2002;23(7):613-618.
52. Schirrmeister H, Kuhn T, Guhlmann A, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001;28(3): 351-358.
53. Thompson CJ, Murthy K, Weinberg IN, et al. Feasibility study for positron emission mammography. Med Phys. 1994;21(4):529-538.
54. Berman CG. Recent advances in breast-specific imaging. Cancer Control. 2007;14(4):338-349.
55. Schilling K, Conti P, Adler A, et al. The role of positron emission mam-mography in breast cancer imaging and management. Appl Radiol. 2008;37 (4):26-36.
56. Tafra L, Cheng Z, Uddo J, et al. Pilot clinical trial of 18F-fluo-rodeoxyglucose positron-emission mammography in the surgical management of breast cancer. Am J Surg. 2005;190(4):628-632.
57. Schilling K. High-resolution positron emission mammography in breast cancer. J Nucl Med. 2007;48(suppl 2):139.
58. Berg WA, Weinberg IN, Narayanan D, et al. High-resolution fluo-rodeoxyglucose positron emission tomography with compression (positron emission mammography) is highly accurate in depicting primary breast cancer. Breast J. 2006;12(4):309-323.
59. Adler OP, Narayanan D, Gammage L. Quantitative improvement in breast lesion detectability on delayed images using high resolution positron emission mamography. J Nucl Med. 2007;48(suppl 2):369P.
60. Raylman RR, Majewski S, Smith MF, et al. The positron emission mammography/tomography breast imaging and biopsy system (PEM/PET): design, construction and phantom-based measurements. Phys Med Biol. 2008;53(3):637-653.
61. Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol. 1993; 11(8):1536-1544.
62. Reynolds JV, Mercer P, McDermott EW, et al. Audit of complete axillary dissection in early breast cancer. Eur J Cancer. 1994;30A(2):148-149.
63. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med. 1998;339(14):941-946.
64. Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999;91(4):368-373.
65. Giuliano AE, Jones RC, Brennan M, et al. Sentinel lymphadenecto- my in breast cancer. J Clin Oncol. 1997;15(6):2345-2350.
66. Leong SP, Morita ET, Treseler PA, et al. Multidisciplinary approach to selective sentinel lymph node mapping in breast cancer. Breast Cancer. 2000;7(2):105-113.
67. Tanaka C, Fujii H, Ikeda T, et al. Stereoscopic scintigraphic imaging of breast cancer sentinel lymph nodes. Breast Cancer. 2007;14(1):92-99.
68. Krynyckyi BR, Kim CK, Goyenechea MR, et al. Clinical breast lym-phoscintigraphy: optimal techniques for performing studies, image atlas, and analysis of images. Radiographics. 2004;24(1):121-145;discussion 139-145.
69. Goyal A, Newcombe RG, Mansel RE, et al. Role of routine preoper-ative lymphoscintigraphy in sentinel node biopsy for breast cancer. Eur J Cancer. 2005;41(2):238-243.
70. Krausz Y, Ikeda DM, Jadvar H, et al. Non-visualization of sentinel lymph node in patients with breast cancer. Nucl Med Commun. 2001;22(1):25-32.
71. Valdes-Olmos RA, Jansen L, Hoefnagel CA, et al. Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification. J Nucl Med. 2000;41(9):1500-1506.
72. Valdes Olmos RA, Tanis PJ, Hoefnagel CA, et al. Improved sentinel node visualization in breast cancer by optimizing the colloid particle concentration and tracer dosage. Nucl Med Commun. 2001;22(5):579-586.
73. van der Ploeg IM, Valdes Olmos RA, Kroon BB, et al. The Hybrid SPECT/CT as an additional lymphatic mapping tool in patients with breast cancer. World J Surg. 2008;32(9):1930-1934.
74. Gallowitsch HJ, Kraschl P, Igerc I, et al. Sentinel node SPECT-CT in breast cancer. Can we expect any additional and clinically relevant information? Nuklearmedizin. 2007;46(6):252-256.
75. van der Ploeg IM, Valdes Olmos RA, Nieweg OE, et al. The additional value of SPECT/CT in lymphatic mapping in breast cancer and melanoma. J Nucl Med. 2007;48(11):1756-1760.
76. Lerman H, Lievshitz G, Zak O, et al. Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med. 2007;48(2):201-206.
77. Ibusuki M, Yamamoto Y, Kawasoe T, et al. Potential advantage of preoperative three-dimensional mapping of sentinel nodes in breast cancer by a hybrid single photon emission CT (SPECT)/CT system. Surg Oncol. 2009 May 11. Epub ahead of print.
78. Mariani G, Erba P, Villa G, et al. Lymphoscintigraphic and intraoper-ative detection of the sentinel lymph node in breast cancer patients: the nuclear medicine perspective. J Surg Oncol. 2004;85(3):112-122.
79. Copeland EM, 3rd. Is axillary dissection necessary for T1 carcinoma of the breast? J Am Coll Surg. 1997;184(4):397-398.
80. Haffty BG, Ward B, Pathare P. Reappraisal of the role of axillary lymph node dissection in conservative treatment of breast cancer. J Clin Oncol. 1997;15:691-700.
81. Maza S, Valencia R, Geworski L, et al. Peritumoural versus subare-olar administration of technetium-99m nanocolloid for sentinel lymph node detection in breast cancer: preliminary results of a prospective intra-individ-ual comparative study. Eur J Nucl Med Mol Imaging. 2003;30(5):651-656.
82. Roumen RM, Geuskens LM, Valkenburg JG. In search of the true sentinel node by different injection techniques in breast cancer patients. Eur J Surg Oncol. 1999;25(4):347-351.
83. Borgstein PJ, Meijer S, Pijpers RJ, et al. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg. 2000;232(1):81-89.
84. Shivers S, Cox C, Leight G, et al. Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol. 2002;9(3):248-255.
85. Kern KA. Sentinel lymph node mapping in breast cancer using sub-areolar injection of blue dye. J Am Coll Surg. 1999;189(6):539-545.
86. McMasters KM, Wong SL, Martin RC, 2nd, et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg. 2001;233(5):676-687.
87. Fleming RM. Mitochondrial uptake of sestamibi distinguishes between normal, inflammatory breast changes, pre-cancers, and infiltrating breast cancer. Integr Cancer Ther. 2002;1(3):229-237.
88. Brem RF, Rapelyea JA, Zisman G, et al. Occult breast cancer: scin-timammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. Radiology. 2005;237(1):274-280.
89. Brem RF, Michener KH, Zawistowski G. Approaches to improving breast cancer diagnosis using a high resolution, breast specific gamma camera. Phys Med. 2006; 21 suppl 1:17-19.
90. Brem RF, Floerke AC, Rapelyea JA, et al. Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology. 2008;247(3):651-657.
91. Rhodes DJ, O'Connor MK, Phillips SW, et al. Molecular breast imaging: a new technique using technetium Tc 99m scintimammography to detect small tumors of the breast. Mayo Clin Proc. 2005;80(1):24-30.
92. O'Connor MK, Phillips SW, Hruska CB, et al. Molecular breast imaging: advantages and limitations of a scintimammographic technique in patients with small breast tumors. Breast J. 2007;13(1):3-11.
93. Yang DJ, Kim EE, Inoue T. Targeted molecular imaging in oncology. Ann Nucl Med. 2006;20(1):1-11.
94. Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43(9):1210-1217.
95. Smyczek-Gargya B, Fersis N, Dittmann H, et al. PET with [18F]flu-orothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2004;31(5):720-724.
96. van Waarde A, Cobben DC, Suurmeijer AJ, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45(4):695-700.
97. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007;72(1):7-25.
98. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
99. Mankoff DA, Link JM, Linden HM, et al. Tumor receptor imaging. J Nucl Med. 2008;49(suppl 2):149S-163S.
100. Katzenellenbogen JA. Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med. 1995;36(6 suppl):8S-13S.
101. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 1997;17(3B):1573-1576.
102. Cummins CH. Radiolabeled steroidal estrogens in cancer research. Steroids. 1993;58(6):245-259.
103. Kiesewetter DO, Kilbourn MR, Landvatter SW, et al. Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25(11):1212-1221.
104. Tewson TJ, Mankoff DA, Peterson LM, et al. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol. 1999;26(8):905-913.
105. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradi-ol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24(18):2793-2799.
106. Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng. 2005;7:287-326.
107. Bolan PJ, Nelson MT, Yee D, et al. Imaging in breast cancer: magnetic resonance spectroscopy. Breast Cancer Res. 2005;7(4):149-152.
108. Morse DL, Raghunand N, Sadarangani P, et al. Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. Magn Reson Med. 2007;58(2):270-280.
109. Morse DL, Carroll D, Day S, et al. Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway. NMR Biomed. 2009;22(1):114-127.
110. Roebuck JR, Cecil KM, Schnall MD, et al. Human breast lesions: characterization with proton MR spectroscopy. Radiology. 1998;209(1):269-275.
111. Gribbestad IS, Singstad TE, Nilsen G, et al. In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging. 1998;8(6):1191-1197.
112. Malycha P, Mountford C. Magnetic resonance spectroscopy and breast cancer. Aust N Z J Surg. 1998;68(12):859-862.
113. Cecil KM, Schnall MD, Siegelman ES, et al. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat. 2001;68(1):45-54.
114. Jagannathan NR, Kumar M, Seenu V, et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer. 2001;84(8):1016-1022.
115. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst. 2002;94(16):1197-1203.
116. Meisamy S, Bolan PJ, Baker EH, et al. Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. Radiology. 2005;236(2):465-475.
117. Sardanelli F, Fausto A, Di Leo G, et al. In vivo proton MR spec-troscopy of the breast using the total choline peak integral as a marker of malignancy. AJR Am J Roentgenol. 2009;192(6):1608-1617.
118. Thomas MA, Binesh N, Yue K, et al. Volume-localized two-dimensional correlated magnetic resonance spectroscopy of human breast cancer. J Magn Reson Imaging. 2001;14(2):181-186.
119. Jacobs MA, Barker PB, Bottomley PA, et al. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging. 2004;19(1):68-75.
120. Hu J, Yu Y, Kou Z, et al. A high spatial resolution 1H magnetic resonance spectroscopic imaging technique for breast cancer with a short echo time. Magn Reson Imaging. 2008;26(3):360-366.
121. Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy - a pilot study at 4 T. Radiology. 2004;233(2):424-431.
122. Sinha S, Lucas-Quesada FA, Sinha U, et al. In vivo diffusion-weighted MRI of the breast: potential for lesion characterization. J Magn Reson Imaging. 2002;15(6):693-704.
123. Hatakenaka M, Soeda H, Yabuuchi H, et al. Apparent diffusion coefficients of breast tumors: clinical application. Magn Reson Med Sci. 2008; 7(1):23-29.
124. Guo Y, Cai YQ, Cai ZL, et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging. 2002;16(2):172-178.
125. Sinha S, Sinha U. Functional magnetic resonance of human breast tumors: diffusion and perfusion imaging. Ann N Y Acad Sci. 2002;980:95-115.
126. Sinha S, Sinha U. Recent advances in breast MRI and MRS. NMR Biomed. 2009;22(1):3-16.
127. Rubesova E, Grell AS, De Maertelaer V, et al. Quantitative diffusion imaging in breast cancer: a clinical prospective study. J Magn Reson Imaging. 2006;24(2):319-324.
128. Kuroki Y, Nasu K. Advances in breast MRI: diffusion-weighted imaging of the breast. Breast Cancer. 2008;15(3):212-217.
129. Marini C, Iacconi C, Giannelli M, et al. Quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesion. Eur Radiol. 2007;17(10):2646-2655.
130. Woodhams R, Matsunaga K, Iwabuchi K, et al. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr. 2005;29(5):644-649.
131. Morse DL, Galons JP, Payne CM, et al. MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed. 2007;20(6):602-614.
132. Galons JP, Altbach MI, Paine-Murrieta GD, et al. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia. 1999;1(2):113-117.
133. Lee KC, Moffat BA, Schott AF, et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res. 2007;13(2 Pt 1):443-450.
134. Pickles MD, Gibbs P, Lowry M, et al. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging. 2006;24(7):843-847.
135. Sharma U, Danishad KK, Seenu V, et al. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed. 2009;22(1):104-113.
136. Theilmann RJ, Borders R, Trouard TP, et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia. 2004;6(6):831-837.
137. Yankeelov TE, Lepage M, Chakravarthy A, et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging. 2007;25(1):1-13.
138. Matsuoka A, Minato M, Harada M, et al. Comparison of 3.0-and 1.5-tesla diffusion-weighted imaging in the visibility of breast cancer. Radiat Med. 2008;26(1):15-20.
139. Lo GG, Ai V, Chan JK, et al. Diffusion-weighted magnetic resonance imaging of breast lesions: first experiences at 3 T. J Comput Assist Tomogr. 2009;33(1):63-69.